IMR Press / EJGO / Volume 30 / Issue 2 / pii/2009041

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Genetic imbalance related to cisplatin-based chemoresistance in epithelial ovarian cancer

Show Less
1 Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang (China)
2 Department of Oncology, The Fifth Hospital of Shenyang, Shenyang (China)
Eur. J. Gynaecol. Oncol. 2009, 30(2), 181–185;
Published: 10 April 2009

Purpose of investigation: To identify genetic imbalance related to chemoresistance in epithelial ovarian cancer. Methods: We screened abnormal chromosomal regions in cisplatin-resistant and cisplatin-sensitive human ovarian cancer cell lines employing comparative genomic hybridization (CGH). We also documented non-random chromosome gains and losses with cisplatin-resistant and cisplatin­sensitive primary epithelial ovarian tumors from patients. Results: There were extensive chromosome changes in cisplatin-resistant and cisplatin-sensitive cell lines. Gains of lq 12-22, 17q21-22 and loss of 3p21-24 were significantly more common in drug-resistant tumors from patients compared to the drug-sensitive group. Conclusions: The special chromosomal aberrances might provide us with a clue for further investigation of the dominant mechanism that leads to a drug-resistant phenotype.

Epithelial ovarian cancer
Comparative Genomic hybridization (CGH)
Back to top